- Home
- OMCL vs RCKT Comparison
OMCL vs RCKT Comparison
Compare OMCL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- RCKT
- Stock Information
- Founded
- OMCL 1992
- RCKT 1999
- Country
- OMCL United States
- RCKT United States
- Employees
- OMCL N/A
- RCKT N/A
- Industry
- OMCL Computer Manufacturing
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- OMCL Technology
- RCKT Health Care
- Exchange
- OMCL Nasdaq
- RCKT Nasdaq
- Market Cap
- OMCL 2.0B
- RCKT 1.3B
- IPO Year
- OMCL 2001
- RCKT N/A
- Fundamental
- Price
- OMCL $44.32
- RCKT $12.72
- Analyst Decision
- OMCL Buy
- RCKT Strong Buy
- Analyst Count
- OMCL 6
- RCKT 11
- Target Price
- OMCL $52.00
- RCKT $50.27
- AVG Volume (30 Days)
- OMCL 513.6K
- RCKT 1.6M
- Earning Date
- OMCL 02-06-2025
- RCKT 02-24-2025
- Dividend Yield
- OMCL N/A
- RCKT N/A
- EPS Growth
- OMCL N/A
- RCKT N/A
- EPS
- OMCL N/A
- RCKT N/A
- Revenue
- OMCL $1,064,205,999.00
- RCKT N/A
- Revenue This Year
- OMCL N/A
- RCKT N/A
- Revenue Next Year
- OMCL $5.24
- RCKT $233,736.97
- P/E Ratio
- OMCL N/A
- RCKT N/A
- Revenue Growth
- OMCL N/A
- RCKT N/A
- 52 Week Low
- OMCL $25.12
- RCKT $11.15
- 52 Week High
- OMCL $55.75
- RCKT $31.47
- Technical
- Relative Strength Index (RSI)
- OMCL 46.46
- RCKT 47.75
- Support Level
- OMCL $42.80
- RCKT $11.56
- Resistance Level
- OMCL $44.69
- RCKT $12.32
- Average True Range (ATR)
- OMCL 1.47
- RCKT 0.71
- MACD
- OMCL -0.12
- RCKT 0.20
- Stochastic Oscillator
- OMCL 34.62
- RCKT 66.81
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.